{"name":"Herbert Lindsley, MD","slug":"herbert-lindsley-md","ticker":"","exchange":"","domain":"","description":"Herbert Lindsley, MD is a specialty pharmaceutical company focused on developing and commercializing innovative treatments. The company has one marketed drug, Standard of Care: Methylprednisolone acetate, which is used for various inflammatory conditions.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Standard of Care: Methylprednisolone acetate","genericName":"Standard of Care: Methylprednisolone acetate","slug":"standard-of-care-methylprednisolone-acetate","indication":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","status":"marketed"}]}],"pipeline":[{"name":"Standard of Care: Methylprednisolone acetate","genericName":"Standard of Care: Methylprednisolone acetate","slug":"standard-of-care-methylprednisolone-acetate","phase":"marketed","mechanism":"Methylprednisolone acetate is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.","indications":["Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)","Allergic and dermatologic conditions","Respiratory inflammatory conditions","Intra-articular and soft tissue injection for localized inflammation"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}